CPT.one Biotech is a privately funded Danish biotech company, dedicated to the development of novel treatments primarily for patients suffering from secondary progressive multiple sclerosis (SP-MS).
CPT-001 is partly in-licensed and further developed by CPT.one Biotech and has a first in class mode of action and block lipid transport in the mitochondria and thereby regulate fat and glucose metabolism. The target is mitochondrial CPT1 and the treatment reestablishes defectives in myelin sheets.
CPT.one welcomes enquiries regarding partnering opportunities.
Company Details
Cpt.one Biotech Questions
Cpt.One Biotech's LinkedIn profile is https://dk.linkedin.com/company/cptone-biotech
Cpt.One Biotech has
1 employees.
View email and phone details for 1
employees at Cpt.One Biotech.
Cpt.One Biotech's industry is
Biotechnology Research
Cpt.One Biotech's top competitors are
Ovodan Biotech A/s,
Health & Hygge,
Milky Way Biotech,
Proxi Biotech,
Health Finder - Din Digitale Lægehjælp På Forskellige Sprog.,
Bojesen And Petersen Biotech,
Health Cover,
Health Clinic Copenhagen,
Bainan Biotech,
Reponex Pharmaceuticals A/s.
Cpt.One Biotech's categories are Biotechnology Research
Cpt.One Biotech's founding year is 2008
